NeuroSense’s PrimeC Shows Promise in ALS Treatment

Neurosense Therapeutics Ltd. (NRSN) has released an update.

NeuroSense Therapeutics has announced promising results from its PARADIGM study, showing that its drug PrimeC significantly slows disease progression and boosts survival rates in ALS patients. The study suggests a 33% improvement in disease progression and a 58% increase in survival rates for those starting treatment with PrimeC, potentially redefining ALS care standards.

For further insights into NRSN stock, check out TipRanks’ Stock Analysis page.